Genomic profiling of intrahepatic cholangiocarcinoma: refining prognosis and identifying therapeutic targets (Q30405398)

19 October 2017

Genomic profiling of intrahepatic cholangiocarcinoma: refining prognosis and identifying therapeutic targets (English)

1 reference

intrahepatic cholangiocarcinoma

19 October 2017

0 references

1 reference

11

1 reference

19 October 2017

Aslam Ejaz

5

0 references

T Yau

object named as

Thomas Yau

12

0 references

Timothy Pawlik

19

object named as

Timothy M Pawlik

1 reference

19 October 2017

2

Darrell R Borger

1 reference

19 October 2017

6

Sorin Alexandrescu

1 reference

19 October 2017

Andrew X Zhu

1

1 reference

19 October 2017

Yuhree Kim

3

1 reference

19 October 2017

David Cosgrove

4

1 reference

19 October 2017

Ryan Thomas Groeschl

7

1 reference

19 October 2017

Vikram Deshpande

8

1 reference

19 October 2017

James M Lindberg

9

1 reference

19 October 2017

Cristina Ferrone

10

1 reference

19 October 2017

Ronnie Poon

13

1 reference

19 October 2017

Irinel Popescu

14

1 reference

19 October 2017

Todd W Bauer

15

1 reference

19 October 2017

T Clark Gamblin

16

1 reference

19 October 2017

Jean Francois Gigot

17

1 reference

19 October 2017

Robert A Anders

18

1 reference

19 October 2017

3 June 2014

1 reference

Annals of Surgical Oncology

19 October 2017

1 reference

19 October 2017

21

1 reference

19 October 2017

12

1 reference

19 October 2017

3827-3834

1 reference

New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing

19 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4324507

Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4324507

The frequency of KRAS and BRAF mutations in intrahepatic cholangiocarcinomas and their correlation with clinical outcome

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4324507

Incidence and prognostic impact of KRAS and BRAF mutation in patients undergoing liver surgery for colorectal metastases

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4324507

Identification of targetable FGFR gene fusions in diverse cancers.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4324507

(R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4324507

Molecular profiling of cholangiocarcinoma shows potential for targeted therapy treatment decisions

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4324507

Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4324507

Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4324507

Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4324507

Genetic profiling of intrahepatic cholangiocarcinoma

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4324507

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4324507

Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4324507

Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4324507

Exploring genomic profiles of hepatocellular carcinoma.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4324507

KRAS and PIK3CA but not BRAF genes are frequently mutated in Chinese cholangiocarcinoma patients

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4324507

Genetics of biliary tract cancers and emerging targeted therapies

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4324507

Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4324507

The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4324507

Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4324507

Pathogenesis of hepatocellular carcinoma and molecular therapies.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4324507

Epidemiology, risk factors, and pathogenesis of cholangiocarcinoma

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4324507

Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase?

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4324507

Aberrant CpG Island Hypermethylation Along Multistep Hepatocarcinogenesis

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4324507

Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4324507

Intrahepatic cholangiocarcinoma.

20 June 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-3828-X

Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-3828-X

Specific TP53 and/or Ki-ras mutations as independent predictors of clinical outcome in sporadic colorectal adenocarcinomas: results of a 5-year Gruppo Oncologico dell'Italia Meridionale (GOIM) prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-3828-X

Frequency of p16(INK4A) alterations and K-ras mutations in intrahepatic cholangiocarcinoma of the liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-3828-X

Isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-3828-X

Exome sequencing identifies distinct mutational patterns in liver fluke-related and non-infection-related bile duct cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-3828-X

Genetic and epigenetic alterations of the INK4a-ARF pathway in cholangiocarcinoma

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24889489

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Rare PIK3CA hotspot mutations in carcinomas of the biliary tract

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24889489

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Exome sequencing of liver fluke-associated cholangiocarcinoma

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24889489

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1245/S10434-014-3828-X

1 reference

Dimensions Publication ID

19 October 2017

0 references

1 reference

19 October 2017

PubMed publication ID

24889489

1 reference